Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study
Samoylenko, Igor V., Demidov, Lev V., Moiseenko, Fedor V., Dvorkin, Mikhail V., Demidova, Svetlana A., Protsenko, Svetlana A., Stroyakovskiy, Daniil L., Kozlov, Vadim V., Odintsova, Svetlana V., Kirtbaya, Dmitry V., Tantsyrev, Denis A., Mochalova, Anastasia S., Orlova, Rashida V., Mukhametshina, Guzel Z., Fadeeva, Natalia V., Fomin, Evgeny A., Chapko, Yana S., Tarasova, Anna V., Ermakov, Nikolay B., Shemerovskiy, Alexander K., Vaschenko, Vera A., Chistyakov, Valery M., Zinkina-Orikhan, Arina V., Lin'kova, Yulia N., Kryukov, Fedor B., Sorokina, Irina V., Siliutina, Anna A.
Published in Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia (10.12.2023)
Published in Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia (10.12.2023)
Get full text
Journal Article